Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 9/20 | 0.45 |
| ▸ | CTSD | P07339 | 5/20 | 0.39 |
| ▸ | AAK1 | Q2M2I8 | 5/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | BCL2 | P10415 | 1/20 | 0.32 |
| ▸ | FPR3 | P25089 | 3/20 | 0.32 |
| ▸ | FPR2 | P25090 | 3/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL446250 | 0.89 | BACE1 (0.42) | BACE1CTSDAAK1 | |
| SCHEMBL449162 | 0.86 | BACE1 (0.46) | BACE1CTSDCYP3A4CYP2C9 | |
| SCHEMBL446897 | 0.85 | BACE1 (0.43) | BACE1CTSD | |
| SCHEMBL2561886 | 0.84 | BACE1 (0.36) | BACE1CTSDCYP3A4CYP2C9 | |
| SCHEMBL447140 | 0.80 | BACE1 (0.45) | BACE1CTSDAAK1CYP1A2CYP3A4 | |
| SCHEMBL448007 | 0.79 | BACE1 (0.56) | BACE1AAK1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL448135 | 0.74 | BACE1 (0.47) | BACE1CTSDCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL445389 | 0.73 | BACE1 (0.65) | BACE1CTSD | |
| SCHEMBL17460950 | 0.73 | BACE1 (0.52) | BACE1 | |
| SCHEMBL15587980 | 0.73 | BACE1 (0.57) | BACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120065195-A1 | COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES | ARRAY BIOPHARMA INC. | 2012-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065195-A1 | COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES | APP, BACE1, PSEN1 | BACE1 2/4885CTSD 427/4885AAK1 1016/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.